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Background: The receptor for advanced glycation endproducts (RAGE) is a viable target for 
early AD diagnosis using positron emission tomography (PET) as RAGE overexpression 
preceeds Aβ plaque formation. The development of a carbon-11 analogue of FPS-ZM1 
([11C]FPS-ZM1), possessing nanomolar affinity for RAGE, may enable the imaging of RAGE 
for early AD detection. Methodology/Results: Herein we report an optimized [11C]CO2-to-
[11C]CO chemical conversion for the synthesis of [11C]FPS-ZM1 and in vitro brain 
autoradiography. The [11C]CO2-to-[
11C]CO conversion via 
11C-silanecarboxylate derivatives 
was achieved with a 57% yield within 30 seconds from EOD. [11C]FPS-ZM1, was obtained 
with a decay-corrected isolated RCY of 9.5%. Conclusions: [11C]FPS-ZM1 distribution in 
brain tissues of wild-type versus transgenic AD-model mice showed no statistically-significant 
difference and high non-displaceable binding. 
 
INTRODUCTION 
Alzheimer’s disease (AD) is the most common subtype of dementia, however is misdiagnosed 
in 30-60% of all cases.[1, 2] Positron emission tomography (PET) enables real-time imaging 
of brain function[3] and AD clinical diagnosis.[4] The use of PET may enable the early 
detection of AD, possibly even 25 years before the onset of the first symptoms.[5]  
The current diagnosis of AD with PET focuses on imaging insoluble beta amyloid (Aβ) plaques 
using radiotracers such as fluorine-18 (18F)-labelled flutemetamol ([18F]flutemetamol, 2-[3-
[18F]fluoro-4-(methyl-amino)-phenyl]-6-benzothiazolol)[6] and carbon-11 (11C)-labelled 
Pittsburgh compound B ([11C]PiB, 2-(4'-[11C]methylaminophenyl)-6-
hydroxybenzothiazole).[7] The deposition of insoluble Aβ plaques, however, almost certainly 
occurs too late in the AD disease process for successful therapeutic intervention and also does 
not always correlate with AD diagnosis or loss of cognition[8, 9] thus limiting the diagnostic 
utility of Aβ-targeting radiotracers.[10, 11] An alternative strategy aims at detecting 
hyperphosphorylated tau protein, the main component of the neurofibrillary tangles 
(NFTs),[12] via the use of specific radiotracers such as [18F]T808.[13] Nevertheless, the 
accumulation of tau NFTs is also observed in frontotemporal dementia,[14] and, additionally, 
may not be present in sufficient amounts to be accurately detected by PET until late stage 
disease.[15] Therefore, to provide an accurate early diagnosis of AD as well as progress in drug 
development, new radiotracers targeting early pathophysiological pathways are crucial.[16, 17] 
The overexpression of the receptor for advanced glycated endproducts (RAGE) is linked with 
AD progression[16, 18] and could represent an alternative strategy for AD imaging. The 
extracellular region of RAGE binds several endogenous ligands, such as S100 calcium-binding 
proteins, advanced glycation endproducts (AGEs) and Aβ peptides and oligomers.[16] The 
binding of neurotoxic Aβ oligomers to RAGE mediates the pre-pathological neurodegenerative 
inflammatory process[19] and triggers AD-related effects, including enhanced activity of Aβ-
producing β-secretase enzyme 1 (BACE1),[20, 21] tau hyperphosphorylation,[22] and 
increased influx of Aβ across the blood brain barrier (BBB).[18, 21] Moreover, RAGE 
activation induces an overexpression of the receptor itself as shown in the brain of patients with 
advanced AD compared to mild AD or healthy controls.[17, 23] In a transgenic mouse model 
of AD (Tg2576) expression of RAGE was highest at the age of 15 months.[21, 24, 25] 
The pathological role of RAGE inspired the development of numerous inhibitors able to block 
the binding of Aβ to its V domain,[16] limiting the detrimental downstream effects. Among 
these inhibitors, a potent small molecule able to selectively bind the V domain of RAGE is the 
tertiary amide-based FPS-ZM1 (N-benzyl-4-chloro-N-cyclohexylbenzamide, Figure 1). FPS-
ZM1 possesses nanomolar affinity for RAGE (inhibitory constant Ki = 25 ± 5 nM)[21] and a 
good in vivo safety profile.[21] In vitro, FPS-ZM1 is able to reduce RAGE-mediated cellular 
oxidative stress, BACE1 mRNA and activity, and nuclear NF-κB levels.[21] In 15-to-18 
month-old Tg2576 mice, FPS-ZM1 (intraperitoneally administered, 1 mg/kg daily for 2 
months) showed a high brain uptake, a decreased influx of Aβ at the BBB to the brain with 
restored cognitive function and cerebral blood flow.[21]  
Based on the good in vitro and in vivo selectivity towards RAGE,[21] FPS-ZM1 was selected 
as a starting structure for the development of RAGE-targeting PET radiotracers. An 18F 
radiolabelled tracer ([18F]fluoro-FPS-ZM1, Figure 1) has been developed by substituting the 
chlorine atom of FPS-ZM1 with fluorine-18 (clogP = 4.9).[26][27] Regional time-activity 
curves in non-human primates and wild type (WT) rodents showed a rapid brain uptake and a 
slow elimination from hippocampal regions[26] – consistent with known RAGE 
expression.[17] Although these in vivo results showed a good uptake in healthy animals, an 
assessment in a Tg2576 mouse model might more accurately predict the biodistribution profile 
of the RAGE radiotracer in a pathological state. Moreover, the use of 11C allows the authentic 
labelling of the unmodified compound, retaining its pharmacodynamic and pharmacokinetic 
profile. A 11C-labelled analogue of FPS-ZM1 ([11C]FPS-ZM1) was therefore developed for 
testing with AD animal models. 
Here we report the incorporation of carbon-11 into the tertiary amide moiety of FPS-ZM1 via 
a 11C-amidation reaction using [11C]carbon monoxide ([11C]CO) as synthon. [11C]CO is a 
versatile synthon that is easily incorporated into a vast array of 11C-carbonyl-containing 
molecules, such as 11C-amides.[27-29] Cyclotron-produced 11C is usually obtained in the form 
of [11C]carbon dioxide ([11C]CO2) and converted to [
11C]CO by: i) gas-phase reduction,[30] ii) 
electrochemical conversion,[31] or iii) chemical conversion via 11C-silanecarboxylate 
derivatives. The latter methodology was recently translated to 11C-chemistry to produce 
[11C]CO via a one-step chemical reaction between [11C]methyldiphenylsilanecarboxylate 
([11C]1) and tetrabutylammonium fluoride (TBAF) (Figure 2) by heating (60 °C) resulting in 
in a modest [11C]CO2-to-[
11C]CO conversion (38 ± 8%).[32] 
The aims of this work were to: i) optimise the [11C]CO2-to-[
11C]CO conversion via [11C]1 by 
studying the variables involved in the [11C]CO production such as temperature, reaction time, 
reagent stability and sample preparation; ii) employ the produced [11C]CO to radiolabel 
[carbonyl-11C]FPS-ZM1 ([11C]FPS-ZM1, Figure 1); and iii) assess [11C]FPS-ZM1 in vitro in 
the brains of wild type (WT) versus Tg2576 mice.  
 
 




General Method and Materials 
All chemicals and dry solvents were purchased from Sigma-Aldrich and Alfa Aesar and used 
as received. Crimp caps (centre hole with 3.0 mm PTFE, seal in aluminium silver 20 mm, 
Fisherbrand, 10132712) and oven-dried reaction v-vial (KX Microwave Vials) were used. All 
the lines used to allow the passage of gases were PTFE tubing (length: 10–20 cm, O.D.: 0.79 
x 0.4 in., I.D.: 1/32 x 0.16 in.). RCYs are based on initial radioactivity of [11C]CO2 and decay 
corrected from EOD. 
 
General Procedure for the Preparation of 3 
2 was added into an oven-dried argon-flushed vial (Vial P) containing lithium and dry THF 
(1.8 mL). The reaction vial was sealed and stirred for 3-24 h at 20 °C under argon. Vial P was 
centrifuged (Jouan, CR 412) at 15 °C and 7000 rpm for 10 min. Subsequently, two aliquots 
(0.45 mL) were transferred under an argon atmosphere (glovebox) to oven-dried argon-flushed 
V-vials (Vial A). 
 
Animals  
All procedures involving animals were conducted in accordance with European Commission’s 
Directive 2010/63/EU. The animals were used in accordance with ethical principles of 
Replacement, Reduction and Refinement.[33] All experiments were performed in tissues of 
17-month-old Tg2576 (n=2) and 8-month-old WT CD-1 (n = 4) mice.  
 
Preparation of Tissues  
Animals underwent anaesthesia with isoflurane (2%) and were sacrificed by decapitation 5 
minutes later. Organs were harvested in isopentane, wrapped in foil and frozen to -80 °C. 
Sagittal 20 µm brain sections were prepared using MNT cryostat (SLEE Medical, Germany) 
as previously described.[7, 26] Two to four sections were mounted onto each SuperFrost® Plus 
blue 90° ground microscopy slide (catalog no. 631-0446, VWR International, UK) and stored 
at -80 °C.  
 
Autoradiography  
After the synthesis, [11C]FPS-ZM1 was reformulated using a Sep-Pack Light C18 cartridge and 
redissolved in a 9:1 water:ethanol mixture. Slides for TB and NDB were defrosted to room 
temperature (2 h prior the incubation), rehydrated in tris-buffered saline (10 min; TBS, pH 7.6) 
and then incubated at room temperature in separate Coplin jars (20 min; catalog no. 12858735, 
Fisher Scientific, UK) containing TBS, the same concentration of [11C]FPS-ZM1 (1-20 nM) 
and either dimethyl-sulfoxide for TB or FPS-ZM1 (10-75 µM) for NDB. Following incubation, 
they were washed in TBS (2 min) and rinsed in deionised water. Slides were then fan-dried and 
exposed to a phosphor imaging plate (30 min; BAS-IP TR 2040, GE Healthcare, UK). The 
plate was scanned using a Typhoon 8600 phosphorimager (GE Healthcare, UK).  
Images were analysed using OptiQuant 5.0 software (PerkinElmer, UK). Cerebellum and 
whole brain region of interests (ROIs) were drawn manually. Qualitative analysis was 
conducted to determine any visual differences between ROIs and animal strains. Quantitative 
binding was expressed as mean normalised digital line units (DLU)/mm2 ± standard deviation. 
Data was analysed using Microsoft Excel 2016 and GraphPad Prism (7.0d). SB was estimated 
as a difference between TB and NDB. All SB data was expressed as % of WT whole brain 
region. WT cerebellum was normalized to whole brain WT to compare the uptake of the tracer 
in the cerebellum relatively to the whole brain. Independent t-tests (statistical significance 
p<0.05) were carried out to compare the variables across ROIs and animal strains.  
 
RESULTS AND DISCUSSION 
 
 
Figure 2. a. Vial P: Li (1.73 mmol), 2 (0.64 mmol), THF (1.8 mL), 3h, r.t. After 3h, an aliquot of Vial P (0.22 – 0.9 mL) is 
transferred in Vial A, which is used for the [11C]CO2 trapping. b. Vial A: [
11C]CO2, r.t., 2 min. c. TBAF (0.8 mmol) added in Vial A, 
then transfer of [11C]CO from Vial A to Vial B with a helium gas stream (60 mL/min). d. Vial B: 12-14 (0.24 mmol), 15-17 (0.01 
mmol), [(cinnamyl)PdCl]2 (0.007 mmol), xantphos (0.007 mmol), solvent (450 μL), 40-120 °C, 2-5 min.  
  
 
Optimization of the [11C]CO2-to-[11C]CO conversion via [11C]1  
In our previous report, the [11C]CO2-to-[
11C]CO conversion was performed in a single vial set-
up (Vial A) yielding 38% of [11C]CO based on total cyclotron produced [11C]CO2 (entry 1, 
Table 1).[32] Briefly, 2 (0.32 mmol, 1.0 equiv., 0.35 mM) reacted with lithium (2.7 equiv.) in 
dry THF (900 μL) at room temperature for 3 h at 20 °C under inert gas atmosphere to give 3.  
[11C]CO2 was subsequently bubbled into Vial A triggering the formation of [
11C]1 (step b, 
Figure 2), which released [11C]CO by heating (60 °C) upon TBAF addition (step c, Figure 2).  
We hypothesized that the excess of unreacted lithium (black particles) contained in Vial A and 
the heating of Vial A were hampering the quantitative conversion of [11C]CO2 to [
11C]CO. To 
reduce the content of unreacted lithium, we opted for the synthesis of 3 in a preparation vial 
(Vial P). Vial P contained 2 (0.64 mmol, 1 equiv., 0.35 mM) and lithium (4 equiv.) in anhydrous 
THF (1.8 mL) and was stirred at room temperature for 3 hours to yield 3 (step a, Figure 2). 
Upon reaction completion, 0.45 mL of the supernatant of Vial P were transferred to an empty 
oven-dried vial (Vial A) under inert gas atmosphere to be used for the [11C]CO2-to-[
11C]CO 
conversion to Vial A. 
 
 
Figure 3. Set up of the two-vial system. A. [11C]CO2 is trapped by Vial A; B. TBAF addition in Vial A promotes the conversion of 
[11C]1 to [11C]CO, which is transferred to Vial B with an helium flush. The transferred [11C]CO will be consumed in Vial B for 
producing [11C]4-10 and [11C]FPS-ZM1. 
 
 
The cyclotron-produced [11C]CO2 was subsequently bubbled into Vial A with high trapping 
efficiency (> 99%, n = 100), leading to the formation of [11C]1 (step b, Figure 2). TBAF was 
added to Vial A at room temperature giving a 47% release of [11C]CO from [11C]1 (entry 2, 
Table 1) within 10 seconds. Thus, excluding the unreacted lithium particles from the mixture 
and performing the TBAF addition at room temperature had a positive effect on [11C]CO 
release, with an increase of [11C]CO production of ~10% (38% in entry 1 versus 47% in entry 
2, Table 1). With the aim of further increasing the production of [11C]CO, we turned our 
attention to the preparation time of 3 by varying the reaction time between 2 and lithium. By 
decreasing the reaction time from 3 hours to 2, 1 and 0.5 hours, no variation on [11C]CO release 
was observed (~50%, entries 3‒5, Table 1). However, when the reaction between 2 and lithium 
was stirred for 0.2 h or 24 h (entries 6-7, Table 1), a detrimental decrease on [11C]CO release 
(3% and 4%, respectively) was observed. A reaction time of 0.2 h might not be enough to 
obtain 3 in good yield, whilst a 24 h reaction formed high amounts of insoluble precipitate 
which might have a negative impact on [11C]CO release. To eliminate the insoluble precipitate, 
centrifugation of Vial P was performed before transferring part of the supernatant solution into 
Vial A. The centrifugation step increased the release of [11C]CO from 4% (entry 7, Table 1) to 
38% (entry 8, Table 1). Similarly, the centrifugation step increased the [11C]CO release when 
2 and lithium were stirred for 3 h (no centrifugation step: 47 ± 4 %, entry 2 versus centrifugation 
included: 57 ± 4%, entry 9, Table 1). Complete trapping of the cyclotron-produced [11C]CO2 
was obtained in each case (> 98%). The centrifugation of Vial P before transferring part of the 
volume into Vial A had a positive effect on [11C]CO production, thus being routinely 
implemented in the method, thereafter. 
As a next step, we examined the effect of the amount of 2 (0.32-1.24 mmol) after either 3 hours 
(entries 10-11, Table 1) or 24 hours (entries 12-13, Table 1) of synthesis time. When the 
amount of 2 was lowered from 0.64 mmol to 0.32 mmol while keeping constant lithium 
equivalents, [11C]CO production dropped from 57% to 8% after 3 hours (entries 9 and 10, 
Table 1) and from 38% to 14% after 24 hours (entries 8 and 12, Table 1). When the amount 
of 2 was increased from 0.64 mmol to 1.24 mmol, [11C]CO production slightly decreased from 
57% to 31% after 3 hours (entries 9 and 11, Table 1) but was unaffected when the reaction was 
stirred for 24 hours (entries 8 and 13, Table 1).  
Further investigations focused on varying the volume of solution transferred form Vial P into 
Vial A whilst keeping constant the concentration of the reagents (0.36 mM of 2). When a 
volume of 0.9 mL (entry 14, Table 1) or 0.225 mL (entry 15) rather than 0.45 mL (entry 9) 
was transferred, the production of [11C]CO decreased from 57% to 38% and 42%, respectively. 
 
Table 1. The effect of reagents amount, reaction time and preparation of Vail A on [11C]CO release via [11C]1. 




Hours Centrifugation  % [11C]CO 
released b 
1[34] 0.64 - 3 No 38 ± 8% 
2 0.64 0.45 3 No 47 ± 4 (5) 
3 0.64 0.45 1 No 56 
4 0.64 0.45 2 No 51 
5 0.64 0.45 0.5 No 54 
6 0.64 0.45 0.2 No 3 
7 0.64 0.45 24 No 4 
8 0.64 0.45 24 Yes 38 ± 3 (3) 
9 0.64 0.45 3 Yes 57 ± 4 (15) 
10 0.32 0.45 3 Yes 8 
11 1.28 0.45 3 Yes 31 
12 0.32 0.45 24 Yes 14 
13 1.28 0.45 24 Yes 35 
14 0.64 0.90 3 Yes 38 
15 0.64 0.22 3 Yes 42 
a Vial P: 2 (1 equiv., 0.64 -1.28 mmol), lithium (4 equiv.), THF (1.8 mL). After 0.1-24 h, 0.22-0.9 mL of solution is 
transferred to Vial A. [11C]CO2 was delivered at 20 
°C for 105 seconds into Vial A. Addition of TBAF 1 M in THF 
(0.8 mmol) after 30 sec of EOD. Vial B: [11C]CO, 12 (0.46 mmol), 15 (0.01 mmol), [(cinnamyl)PdCl]2 (0.007 mmol), 
xantphos (0.007 mmol), THF (0.5 mL), 25 °C.  
b  The % [11C]CO released was calculated dividing the amount of radioactivity in Vial B over the total radioactivity (Vial 





To further optimise the reaction, we focused on the effect on [11C]CO release of varying the 
amount of TBAF added to [11C]1 and the interval times between TBAF addition and [11C]CO2 
delivery. A range of TBAF concentrations (0.4-1.6 mmol, entries 1-3, Table SI1) were added 
to [11C]1 after 30 seconds from end of [11C]CO2 delivery (EOD). The use of 0.8 mmol of TBAF 
granted a [11C]CO release of 57% (entry 1, Table SI1).  Reducing or increasing the TBAF 
content to 0.4 or 1.6 mmol lowered the [11C]CO release (24% and 19%, respectively, entries 
2-3, Table SI1). Subsequently, a study on the interval (30 seconds, 5 and 30 minutes) between 
EOD and TBAF addition was performed. High [11C]CO release was achieved when TBAF 
solution was added within 5 min from EOD (55%, entry 4, Table SI1). On the contrary, the 
addition of TBAF after 30 min from EOD gave low [11C]CO yields (28%, entry 5, Table SI1) 
probably due to potential degradation of [11C]1 in the reaction mixture. 
In summary, the highest [11C]CO release from [11C]1 (57% (n = 15), entry 9, Table 1) was 
achieved when: 1) 0.64 mmol (1 equiv.) of 2 reacted with lithium (4 equiv.) in 1.8 mL of THF 
for 3 hours at room temperature; 2) 0.45 mL of the supernatant solution were transferred in 
Vial A after centrifuging the reaction mixture contained in Vial P; 3) the [11C]CO2 delivery 
into Vial A was performed at room temperature; and 4) 0.8 mmol of TBAF were added 30 
seconds post EOD.  
 
Radiosynthesis of [11C]4-10 and [11C]FPS-ZM1  
The optimized conditions for [11C]CO production (entry 9, Table 1) were applied to the 
radiolabeling of [11C]4-10 and [11C]FPS-ZM1. A second oven-dried v-shaped reaction vial 
(Vial B) was preloaded with Pd(π-cinnamyl)chloride ([(cinnamyl)PdCl]2), xantphos, 
benzylamine (12-14) and iodobenzene (15-17) derivatives in anhydrous THF under nitrogen. 
(step d, Figure 2). Once [11C]CO was transferred into Vial B, it was consumed in a Pd-
mediated 11C-carbonylation reaction forming 11C-benzylbenzamide derivatives ([11C]4-10 and 
[11C]FPS-ZM1).[32] A sodium hydroxide-coated silica (ascarite) trap was placed between the 
two vials to capture any untrapped [11C]CO2 (Figure 2).  
The strategy to synthesize [11C]FPS-ZM1 was developed starting from previous studies on an 
analogue compound ([11C]benzylbenzamide, [11C]4) obtained in high radiochemical yield 
(RCY > 99%) by coupling benzylamine (12) with iodobenzene (15).[32, 34] Compared to 
[11C]4 (Table 2), [11C]FPS-ZM1 bears a tertiary amide, a bulky cyclohexyl group and a 
chlorine atom in para-position to the amide group. The influence of these chemical features 
was explored by combining primary and secondary amines (12-14, Figure 3, Table 2) with 
different para-iodo aryl halides (15-17). 
 
 
Table 2. Effects of substituents R1 and R2 on RCY and chemical structures of the 
11C-labelled products 
   
Product Amine Iodobenzene 
derivative 
R1 R2 RCY (%) 
a 
[11C]4 12 15 H H >99% b 
[11C]5 13 15 CH3 H 80% 
b 
[11C]6 14 15 cyclohexyl H 37% b 
[11C]7 12 16 H F >99%  b 
[11C]8 14 16 cyclohexyl F 36% b 
[11C]9 12 17 H Cl 74% b 
[11C]10 13 17 CH3 Cl 52% 
b 
[11C]FPS-ZM1 14 17 cyclohexyl Cl 30.2 ± 5.3% c 
a 9-11 (0.24 mmol), 12-14 (0.01 mmol), [(cinnamyl)PdCl]2 (0.007 mmol), xantphos (0.007 mmol), THF (450 μL), 5 min, 100 °C.  
RCY is the percentage of of product radioactivity divided by total radioactivity observed in an analytical HPLC chromatogram. 
b n = 1;  




The substitution of a hydrogen atom of the benzylamine (12) with a methyl group (N-
benzylmethylamine, 13) aimed to elucidate the reactivity of a secondary amine substituted with 
a low sterically-hindered group. This modification lowered the RCY to 80% ([11C]5, Table 2). 
The lowered reactivity is more pronounced when a bulkier cyclohexyl group (N-
benzylcyclohexanamine, 14) is introduced ([11C]6, RCY = 37%).  
The same trend was observed using p-iodo fluorobenzene (16) and p-iodo chlorobenzene (17). 
Indeed, when 16 reacted with 14, the RCY was lower compared to the reaction with the least 
sterically-hindered 12 ([11C]8, RCY = 36% versus [11C]7, RCY > 99%, Table 2). 17 showed 
the same RCY decrease when coupled with 12 ([11C]9, RCY = 74%), 13 ([11C]10, RCY = 52%) 
and 14 ([11C]11, RCY = 30.2%, Table 2). Thus, switching from a primary to a secondary amine 
and increasing the steric hindrance on the amine partly impedes the reaction irrespective of the 
p-iodoaryl halide derived used. 
Varying the para substituent (R2) of iodobenzene also affected the RCY of the reaction (Table 
2). The presence of a hydrogen (15) or a fluorine (16) showed the same RCY when either 
amines 12 ([11C]7, RCY > 99% versus [11C]4, RCY > 99%) or 14 ([11C]8, RCY = 36% versus 
[11C]6, RCY = 37%) were used.  
The insertion of a chlorine atom (17) in para position of the iodobenzene instead significantly 
diminished the RCY of the reaction compared to 15 ([11C]9, RCY = 74% versus [11C]4, RCY 
> 99%; [11C]10, RCY = 52% versus [11C]5, RCY = 80%; [11C]FPS-ZM1, RCY = 30% of 
versus [11C]6, RCY = 37%, Table 2).  
To increase the RCY of [11C]FPS-ZM1 (RCY = 30.2 ± 5.3%), different variables were also 
investigated: temperature, addition of a base, concentration of 14 and solvent (Table SI2). 
Decreasing the temperature from 100 °C to 40 °C (entry 1, Table SI2) did not yield the product 
whereas increasing the temperature to 120 °C lowered the RCY from 30% to 14% (entry 2, 
Table SI2). The addition of a base, such as NEt3, to increase the nucleophilicity of 14 was 
detrimental for the reaction (entry 3, Table SI2). Doubling the concentration of 14 from 0.24 
mmol to 0.48 mmol did not improve the RCY (RCY = 14%, entry 4, Table SI2). Furthermore, 
solvents other than THF were tested: dioxane (RCY = 15%, entry 5, Table SI2) and acetonitrile 
(ACN, RCY = 9%, entry 6, Table SI2) were associated with a lower RCY of [11C]FPS-ZM1.  
In conclusion, the optimal conditions for [11C]FPS-ZM1 production are obtained when 0.24 
mmol of 14 are reacted with 0.01 mmol of 17 at 100 °C in anhydrous THF for 5 minutes (Table 
2). With these conditions, [11C]FPS-ZM1 was produced with a decay-corrected isolated RCY 
of 9.5 ± 1.5% and radiochemical purity (RCP) > 99% within 24 minutes from end of cyclotron 
target bombardment (EOD), resulting in an activity yield of 3.3 ± 1.4% based on an initial 
[11C]CO production of ~100 MBq. The molar activity of the final product was 0.77 ± 0.13 
GBq/μmol decay-corrected at EOD starting with an initial [11C]CO2 delivery of 300 MBq. This 
method was adopted for the synthesis of [11C]FPS-ZM1 to be tested in in vitro experiments. 
 
Autoradiography 
One of the key requirements for a central nervous system PET radiotracer is high binding 
affinity towards its molecular target and low non-specific binding.[35, 36] The binding profile 
of [11C]FPS-ZM1 against RAGE was evaluated in brain sections of WT and 17-month Tg2576 
mice. 
The binding was assessed in the whole brain (minus cerebellum) and the cerebellum. Total 
binding (TB) was confirmed at varying concentrations of [11C]FPS-ZM1 (5-10 nM) whereas 
non displaceable binding (NDB) was determined in the presence of differing concentration of 
non-radioactive FPS-ZM1 (25-75 µM). Specific binding (SB) was obtained by subtracting the 
signal of NDB from TB.  
Qualitative and quantitative analysis was conducted at three sets of concentrations (A-C):  
A: TB: 10 nM of [11C]FPS-ZM1 and NDB: 10 nM of [11C]FPS-ZM1 with 25 µM of FPS-
ZM1; B: TB: 10 nM of [11C]FPS-ZM1 and NDB: 10 nM of [11C]FPS-ZM1 with 75 µM of 
FPS-ZM1; C: TB: 5 nM of [11C]FPS-ZM1 and NDB: 5 nM of [11C]FPS-ZM1 with 75 µM of 
FPS-ZM1.  
Qualitative image analysis using 10 nM of [11C]FPS-ZM1 showed high NDB of [11C]FPS-
ZM1 (sets A and B) in WT and Tg2576 mice. By lowering the concentration of [11C]FPS-
ZM1 from 10 nM  to 5 nM (set C), a lower degree of NDB was observed in WT and Tg2576 
mice (Figure 3A). Thus, set C was chosen for quantitative autoradiography analysis to enable 
a comparison with qualitative images.  
Although qualitative images showed an increase in SB of [11C]FPS-ZM1 in the whole brain 
of Tg2576 versus WT mice (49%, Figure 3A-B), this difference was not statistically significant 
when a quantitative autoradiography analysis was performed (Figure 3B).  
 
Figure 4. A. Qualitative autoradiography comparison of TB and NDB signals in WT and Tg2576 at concentration set C. B. SB of 
[11C]FPS-ZM1 in WT and Tg2576 mouse brain normalised to WT whole brain at concentration set C. Set C: TB: 5 nM of [11C]FPS-
ZM1 and NDB: 5 nM of [11C]FPS-ZM1 with 75 µM of FPS-ZM1. 
       
All values are expressed as % WT whole brain SB ± standard deviation and were derived from 3 independent quantitative 
autoradiography experiments. WT cerebellum value was normalized to the whole brain SB. The black-circled area indicates 
the cerebellum, whereas the red-circled area is the whole brain (minus cerebellum). Autoradiographic images are displayed 





In summary, a rapid and reliable method for the chemical conversion of [11C]CO2 to [
11C]CO 
via [11C]1 at room temperature was achieved with a [11C]CO release of up to 57% within 30 
seconds from EOD based on total radioactivity delivered. The produced [11C]CO was 
employed for the synthesis of a novel 11C-PET-based RAGE radiotracer via Pd-catalyzed 
[11C]CO amidation, [11C]FPS-ZM1, which was obtained with a decay-corrected isolated RCY 
of 9.5%. The in vitro evaluation of [11C]FPS-ZM1 showed a 49% greater SB signal in the 
whole brain of Tg2576 versus WT mice, however this was non-statistically significant. 
Moreover, a high degree of NDB was observed. Poor radiotracer displacement may be 
explained by its high lipophilicity (calculated LogP for FPS-ZM1 = 5.25)[37] leading to 
increased NDB to lipids (e.g. cell membrane).[38] This barrier may be overcome by modifying 
the lipophilicity of future radiotracers derived from this pharmacophore for imaging RAGE.  
 
FUTURE PERSPECTIVES 
Although at present AD progression cannot be halted or reversed, the availability of a RAGE 
radiotracer for PET imaging would enable the monitoring of brain RAGE levels from 
presymptomatic to late stage AD and establish a temporal relationship between 
neuroinflammation, RAGE expression, amyloid-β plaque and neurofibrillary tangle formation 
as well as a providing a tool for determining target occupancy of RAGE inhibitors. The findings 
outlined in this study and others[26] pave the way for the development of a second generation 
of RAGE PET radiopharmaceuticals with optimal lipophilicity profiles commensurate with 
improved in vivo imaging signal-to-noise ratios. Longitudinal studies determining the in vivo 
brain uptake in AD animal models using both RAGE and ß-amyloid PET radiotracers would 
enable the evaluation of RAGE as and early AD biomarker. assisting the discovery of new 
therapies. In the longer term, RAGE PET radiotracers may allow the development and 
evaluation of new disease-modifying treatments as well as an early diagnostic tool for AD. 
 
SUMMARY POINTS 
• The Receptor for Advanced Glycated Endproducts (RAGE) is involved in the 
neuroinflammatory pathway in Alzheimer’s Disease (AD) and found to be 
overexpressed in early pre-AD pathology. 
• FPS-ZM1, reported by Deane at al., is a RAGE inhibitor which is able to restore 
cognitive function in AD mouse models (Tg2576). The radiolabelling of FPS-ZM1 
would allow the imaging of in vivo RAGE expression and its early involvement with 
disease progression. 
• [11C]CO chemistry allows rapid radiolabelling of the amide moiety of FPS-ZM1. A 
novel [11C]CO2-to-[
11C]CO conversion via 11C-silanecarboxylate derivatives was 
optimized and then applied to the radiolabeling of [11C]FPS-ZM1. 
• In vitro autoradiography studies with [11C]FPS-ZM1 showed a non-statistically 
significant difference in specific binding in AD-mouse model (Tg2576) brains 
compared to wild-type mouse brains. A high non-displaceable binding was observed, 
probably due to the high lipophilicity of [11C]FPS-ZM1.  
• Follow-up studies using more hydrophilic probes to lower the non-displaceable binding 
are needed to correlate RAGE expression and early AD stages in vivo.  
 
ABBREVIATIONS USED 
[11C] – carbon-11-labelled radiotracer; [11C]CO – carbon-11 labelled carbon monoxide; 
[11C]CO2 – carbon-11 labelled carbon dioxide; [
18F] – fluorine-18-labelled radiotracer; Aβ – 
beta amyloid; AD – Alzheimer’s disease; AGEs – advanced glycation endproducts; BACE1 - 
β-secretase enzyme 1; BBB – blood brain barrier; 11C – carbon-11; EOB – end of 
bombardment; EOD – end of [11C]CO2 delivery; 
18F – fluorine-18; NDB – non-displaceable 
binding; NFT – neurofibrillary tangle; PET – positron emission tomography; RAGE – receptor 
for advanced glycation endproducts; RCP – radiochemical purity;  RCY – radiochemical yield; 
ROI – region of interest; SB – specific binding; TB – total binding; TBAF  –  tetrabutyl 
ammonium fluoride; TG – transgenic; WT – wild-type;  
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